Early promise of blood marker to detect mesothelioma

November 13, 2003

Preliminary results of a study in this week's issue of THE LANCET suggest that a blood test could be used in the future to identify people with mesothelioma-the usually deadly malignant tumor of mesothelial tissue surrounding the lungs, often caused by exposure to asbestos.

Bruce Robinson from Sir Charles Gairdner Hospital, Perth, Australia, and colleagues developed a test to assess blood concentrations of proteins expressed by mesothelioma cells (soluble mesothelin-related proteins [SMR]). The test had a high level of specificity: 37 (84%) of 44 patients with mesothelioma had raised concentrations of SMR compared with three (2%) of 160 patients with other cancers or other inflammatory lung or pleural diseases, and with none of 28 controls who had not been exposed to asbestos.

The investigators suggest that SMR could be a useful way to monitor the tumor's growth as concentrations correlated with tumour size and increased during tumour progression.

Bruce Robinson comments: "On the basis of our data we propose that measurement of SMR concentrations in serum is a useful adjunct in the diagnosis of mesothelioma. Blood SMR concentrations should be monitored in asbestos-exposed individuals who are at risk of developing mesothelioma to determine if early therapeutic intervention improves patients' outcome."

He adds: "Importantly for the hundreds of thousands of asbestos-exposed people who are at risk of this cancer, the test can detect the cancer several years before it presents. Of seven asbestos-exposed individuals who had increased blood concentrations of SMR, three developed mesothelioma and one developed lung cancer within 1-5 years whereas none of the 33 asbestos-exposed participants whose blood samples had normal concentrations of SMR developed mesothelioma in that time."
Contact: Sharene Chatfield, Public Relations Manager, Sir Charles Gairdner Hospital, Perth, Australia;
T) 61-8-9346-2404;
M) 61-417-937229;
E) Sharene.Chatfield@health.wa.gov.au

Lancet 2003; 362: 1612-16


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.